Active Pharmaceutical Ingredients Market

Active Pharmaceutical Ingredients Market Size & Growth (2019 - 2025)

The global active pharmaceutical ingredients market size is expected to reach USD 216 billion by 2019 and expected to register a CAGR of 6.3% from 2019 to 2025.

Improvement of prices and also the government policies with a large number of preparations of drug activities providing growth opportunities to the market. Companies cannot prepare a generic drug unless the patent of the drug expires. But, when the drug loses its license, the other drug manufacturers grab the opportunity to make the low-cost generics and also file for ANDA to the U.S. F.D.A. It is possible to carry out an in-depth SWOT (strengthens, weakness, opportunities, and threats) analysis, that can decide the segment they wish to target based on the strengths and weakness of competitor.

In addition, the emerging biosimilar market, the growing reach of HPAPI solutions, emerging markets and emerging technologies have opened up a range of opportunities for the global active pharmaceutical ingredients market growth.

However, factors such as strict regulatory requirements and unfavorable drug price control policies in several countries can slow down the growth of the Global active pharmaceutical ingredients market.

Factors such as lessening or shortening the developing time, cost of the development to be reduced, improving the process design and without compromising the gain or profits, a meeting of the standard quality are the challenges on the other side.

The global active pharmaceutical ingredients market is marked by violent criminal competition, and it is challenging, and it is not possible for any new entrants to enter the production of an excellent profit market.

Key happenings in this market in the recent past:

• On February 26, 2020, Sun Pharmacy has launched the Riomet ER in the U.S. an adjunct to diet and exercise to improve glycemic control.
• On February 18, 2020, Boehringer- Ingelheim launches patient Centric MyStudioWindow powered by Carebox.
• On February 07, 2020, Dr Reddy’s along with his subsidiaries, launched the Trientine Hydrochloride Capsules, USP, 250 which was approved by the FDA. 
• On February 07, 2020, Dr Reddy’s and its unit enters the Amendment of Agreement with Aurigene Discovery Technologies.
• On February 27, 2020, Dr Reddy’s laboratories have announced the launch of naproxen and esomeprazole magnesium delayed-release tablets which was approved by the FDA.
• In June 2019, Primal Pharma solutions announced its lab space extension of its Michigan, which is a U.S based facility. This facility is dedicated to the high power of something to influence the active pharmaceutical ingredients.

REPORT COVERAGE:

This research report on the Global Active Pharmaceutical Ingredients Market segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2025.

Active Pharmaceutical Ingredients Market Analysis – By Type of Manufacturing Process:

• Captive Manufacturing
• Contract Manufacturing

On the basis of the manufacturing process, the captive manufacturer's segment is estimated to account for the largest share in 2019. The large share of this segment can be attributed to the growing preference of companies to maintain in-house manufacturing of innovative APIs for their economic benefits.

Active Pharmaceutical Ingredients Market Analysis – By Type of Synthesis:

• Synthetic
• Biotech

On the type of synthesis, the synthetic segment is expected to be the largest in 2019. The emergence of new molecules in the market, the increasing number of approvals for new products and technological advances in the synthesis method are the main contributors to the growth of the Segment. However, the biotechnology API segment is expected to grow at the highest CAGR during the forecast period.

Active Pharmaceutical Ingredients Market Analysis – By API Formulation:

• Generic API
• Innovative API

On the basis of API formulation, the innovative API segment is expected to account for the majority in 2019. The large share of this segment can be attributed to the increasing number of FDA approvals for new molecular entities, higher price commanded by innovative APIs as compared to their generic equivalents, and growing focus of innovator APIs companies on R&D for the development of novel innovative API products to cater to the unmet medical needs of the Global active pharmaceutical ingredients market.

Active Pharmaceutical Ingredients Market Analysis – By Application:

• Cardiovascular Diseases
• Oncology
• Neurological Disorders
• Orthopedic Disorders
• Respiratory
• Gastrointestinal Disorders
• Urology
• Others

Active Pharmaceutical Ingredients Market Analysis – By Molecule:

• Large Molecule
• Small Molecule

Active Pharmaceutical Ingredients Market Analysis – By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa

Regionally, the Asia-Pacific is expected to register a high growth rate compared to other regions during the forecast period in the Global Active Pharmaceutical Ingredients Market, owing to the factors such as increasing healthcare expenditures, growing aging population that create a huge patient pool, and rising economies in this region. China is considered to be the leader in API manufacturing in the APAC region. There are many domestic companies involved in the manufacturing and supplying of API all over the world. Not just in the Asia-Pacific region, China exports the major share of its domestically produced API around the world.

List of key market participants leading the Global Active Pharmaceutical Ingredients Market profiled in this report are:

1. Sanofi 
2. Bayer AG
3. Pfizer Inc.
4. F. Hoffmann-La Roche AG
5. Abbott Laboratories
6. Merck & Co., Inc.
7. Boehringer Ingelheim GmbH
8. Glaxosmithkline Plc (GSK)
9. Novartis AG
10. Eli Lilly and Company
11. Teva Pharmaceutical Industries Ltd